Biosimilars

Nine adalimumab biosimilars entered the market in 2023, which will have a significant impact on access to life-altering therapies. The ACR has compiled a list of internal and external resources on biosimilars for providers, including what they are, how they work, what it means for patients, and possible coverage considerations. More information and resources will be added as they become available.

ACR Biosimilar Resources

• Position Statement on Biosimilars
• Biosimilars Patient Fact Sheet
• ACR on Air Podcast: Biosimilars (January 2023)
• The Rheumatologist: The Biosimilar Economic Conundrum: Where We Stand
• The Rheumatologist: Marching to the Biosimilar Beat: Questions on Rollout Remain

ACR Policies and Statements on Biologics

• Patient Safety and Site of Service for Infusible Biologics
• Complexity of Biologics
• Biosimilar Health Policy Statements
• Policy Priorities: Access to Biosimilars
• Principles on Prescription Drug Prices and Access to Treatment

Additional Resources

• Centers for Medicare and Medicaid Services (CMS) Inflation Reduction Act (IRA) Biosimilars Temporary Payment Increase FAQs
• Food and Drug Administration Biosimilars Resource Center
• The Center for Biosimilars: The Age of Adalimumab Is Upon Us: How Stakeholders Can Prepare
• Biologics Prescribers Collaborative
• American Society for Hospital Pharmacists (ASHP) Biosimilars Resources
• American Pharmacist Association (APhA): Overview of Biologics and Biosimilar Products